Article
Oncology
Ally Fraser, Paul Castillo, Erika Cascio, Giselle Moore-Higgs, Nosha Farhadfar, John Fort, William Slayton, Jatinder Lamba, Biljana Horn
Summary: This study aimed to determine the minimum effective dose (MED) of thiotepa in combination with reduced-dose busulfan, fludarabine or cyclophosphamide, and rATG to achieve engraftment in >90% of HSCT recipients with non-malignant disorders. The results showed that all six patients achieved engraftment prior to Day +42 and none of them experienced disease recurrence.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Hematology
Claire Seydoux, Michael Medinger, Sabine Gerull, Joerg Halter, Dominik Heim, Yves Chalandon, Stavroula Masouridi Levrat, Urs Schanz, Gayathri Nair, Marc Ansari, Patrick Simon, Jakob R. Passweg, Nathan Cantoni
Summary: Reversing the order of application of cyclophosphamide and busulfan in myeloablative conditioning for allo-HCT patients may lead to better outcomes. Short-term results show advantages of CyBu over BuCy in terms of liver toxicity, while long-term follow-up demonstrates lower non-relapse mortality and higher survival with CyBu compared to BuCy.
ANNALS OF HEMATOLOGY
(2021)
Article
Hematology
Kimimori Kamijo, Yoshimitsu Shimomura, Akihito Shinohara, Shohei Mizuno, Minoru Kanaya, Yoshiaki Usui, Sung-Won Kim, Takahide Ara, Ishikazu Mizuno, Takuro Kuriyama, Hideyuki Nakazawa, Ken-ichi Matsuoka, Shigeru Kusumoto, Nobuo Maseki, Masaki Yamaguchi, Takashi Ashida, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Eisei Kondo
Summary: By comparing the effects of Flu/Bu2 and Flu/Bu4 on patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation, the study found that Flu/Bu4 was associated with higher nonrelapse mortality and lower 5-year overall survival compared to Flu/Bu2.
ANNALS OF HEMATOLOGY
(2023)
Review
Health Care Sciences & Services
Heather R. Wolfe, Mitchell E. Horwitz, Lindsay A. M. Rein
Summary: Primary myelofibrosis is a BCR-ABL1 negative myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells. Allogenic hematopoietic stem cell transplantation may provide a safe and effective curative option for a broader range of primary myelofibrosis patients in the future.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Ga-Young Song, Sung-Hoon Jung, Jin Seok Kim, Hyeon Seok Eom, Joon Ho Moon, Ho-Young Yhim, Kihyun Kim, Chang-Ki Min, Je-Jung Lee
Summary: This study compared the efficacy and toxicity of the conditioning regimens busulfan and thiotepa (BuTT) and high-dose melphalan (HD-MEL) for autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (MM). The results showed that the overall response rate after ASCT was similar between BuTT and HD-MEL, but the BuTT group had a longer progression-free survival (PFS) and fewer adverse events.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biophysics
Anne Banet, Ali Bazarbachi, Myriam Labopin, Nicolas Stocker, Remy Dulery, Florent Malard, Zoe Van de Wyngaert, Alexis Genthon, Mara Memoli, Ollivier Legrand, Agnes Bonnin, Tounes Ledraa, Ramdane Belhocine, Simona Sestili, Jean El-Cheikh, Mohamad Mohty, Eolia Brissot
Summary: Total body irradiation (TBI)-based conditioning regimens are commonly used in acute lymphoblastic leukemia (ALL) patients, but studies have shown comparable outcomes with thiotepa-based conditioning regimen. In this retrospective study, we evaluated the outcome of adult ALL patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HCT) with a thiotepa-busulfan-fludarabine (TBF) myeloablative conditioning regimen. The results showed promising overall survival and acceptable toxicity in these patients.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Mara Memoli, Annalisa Paviglianiti, Florent Malard, Giorgia Battipaglia, Eolia Brissot, Clemence Mediavilla, Antonio Bianchessi, Anne Banet, Zoe Van de Wyngaert, Tounes Ledraa, Ramdane Belhocine, Simona Sestili, Simona Lapusan, Pierre Hirsch, Fabrizia Favale, Agathe Boussaroque, Agnes Bonnin, Anne Vekhoff, Ollivier Legrand, Mohamad Mohty, Remy Dulery
Summary: This study assessed the outcomes of 29 MF patients who underwent transplantation with the TBF regimen, finding it to be an effective conditioning strategy with a 69% overall survival rate and no observed relapses.
LEUKEMIA & LYMPHOMA
(2021)
Article
Hematology
Daniel P. Noij, Martin van den Bent, Jeanette K. Doorduijn, Nick Wlazlo
Summary: We report a case of a 19-year-old patient who experienced two episodes of donor-derived PCNSL after undergoing allogeneic stem cell transplantation in childhood. Despite failed induction chemotherapy, successful consolidation therapy was achieved through a second allogeneic stem cell transplantation after conditioning with thiotepa, busulfan, and fludarabine.
ACTA HAEMATOLOGICA
(2023)
Article
Pharmacology & Pharmacy
Ai-Hoc Nguyen, Mohitosh Biswas, Apichaya Puangpetch, Santirhat Prommas, Samart Pakakasama, Usanarat Anurathapan, Jiratha Rachanakul, Rattanaporn Sukprasong, Nutthan Nuntharadtanaphong, Nutcha Jongjitsook, Suradej Hongeng, Chonlaphat Sukasem
Summary: This study found a significant association between the polymorphism of GSTA1 and variations in the pharmacokinetic properties of busulfan treatment in pediatric Asian patients. Patients carrying the GSTA1*B variant showed a significant impact on the PK of busulfan, with a notable augmentation in AUC.
Article
Hematology
Jacinth Joseph, Samer A. Srour, Denai R. Milton, Jeremy L. Ramdial, Neeraj Y. Saini, Amanda L. Olson, Qaiser Bashir, Betul Oran, Amin M. Alousi, Chitra Hosing, Muzaffar H. Qazilbash, Partow Kebriaei, Elizabeth J. Shpall, Richard E. Champlin, Uday R. Popat
Summary: In patients with myelofibrosis (MF) who underwent allogeneic stem cell transplantation (allo-SCT), using a uniform myeloablative conditioning regimen and methotrexate-based graft-versus-host disease prophylaxis, donor choice and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) were found to be the two strongest predictors for improved survival.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Naveed Ali, Ashish Arunkumar Sharma, Ana Carolina Pires de Rezende, Folashade Otegbeye, Bilal Muhammad Latif, Mariana Nassif Kerbauy, Brenda W. Cooper, Gabriela Sanchez, Leland Metheny, Saswat K. Bal, Roberto Sakuraba, Benjamin K. Tomlinson, Kirsten M. Boughan, Lucila Kerbauy, Ehsan Malek, Andreza Feitosa Ribeiro, Molly Gallogly, David Mansur, Gisele Pereira, Eduardo Weltman, Rafick-Pierre Sekaly, Marcos de Lima, Paolo F. Caimi, Nelson Hamerschlak
Summary: This study evaluated the efficacy of intensified fludarabine/busulfan (Flu/Bu) reduced-intensity conditioning (RIC) regimen with targeted marrow irradiation (TMI) in high-risk hematologic malignancies patients. The results showed that this approach was feasible with low transplantation-related mortality in medically frail patients with advanced malignancies.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Shlomo Elias, Samantha Brown, Sean M. Devlin, Juliet N. Barker, Christina Cho, David J. Chung, Parastoo B. Dahi, Sergio Giralt, Boglarka Gyurkocza, Ann A. Jakubowski, Oscar B. Lahoud, Heather Landau, Richard J. Lin, Esperanza B. Papadopoulos, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Brian C. Shaffer, Gunjan L. Shah, Roni Tamari, James W. Young, Miguel-Angel Perales, Roni Shouval
Summary: Comorbidity assessment is important before allogeneic haematopoietic cell transplantation (allo-HCT) to estimate non-relapse mortality (NRM) risk. The Simplified Comorbidity Index (SCI), which includes a small number of comorbidities and older age, has been shown to predict NRM. In this study, we validated the SCI in patients receiving reduced-intensity conditioning followed by allo-HCT from HLA-matched donors. Higher SCI scores were associated with increased NRM risk and reduced overall survival. These findings suggest that the SCI is a reliable tool for risk stratification in allo-HCT candidates.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Yuan-Yuan Shi, Zeng-Yan Liu, Gui-Xin Zhang, Yi He, Ming-Zhe Han, Si-Zhou Feng, Rong-Li Zhang, Er-Lie Jiang
Summary: This study explores the safety and effectiveness of a cladribine-based conditioning regimen for autologous hematopoietic stem cell transplantation in patients with acute myeloid leukemia. The results indicate that this regimen is a successful and safe approach for AML treatment.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Qiang Zeng, Hang Zhang, Pu Kuang, Jian Li, Xinchuan Chen, Tian Dong, Qiuhui Wu, Chuanli Zhang, Chunping Chen, Ting Niu, Ting Liu, Zhigang Liu, Jie Ji
Summary: The conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan (ChiCGB) was effective in improving the prognosis of patients with peripheral T-cell (PTCL) or lymphoblastic T-cell lymphoma (T-LBL) undergoing autologous stem cell transplantation (ASCT). The regimen resulted in favorable overall survival and progression-free survival, with manageable adverse events. Randomized controlled trials are needed to further evaluate ChiCGB as a conditioning regimen for ASCT.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jie Ji, Zhigang Liu, Pu Kuang, Tian Dong, Xinchuan Chen, Jian Li, Chuanli Zhang, Jiazhuo Liu, Li Zhang, Kai Shen, Ting Liu
Summary: The study demonstrates the safety and efficacy of the chidamide-cladribine-gemcitabine-busulfan combination in high-risk and refractory/relapsed lymphomas. The overall survival rate reached 86.1%, with B-NHL patients showing a higher survival rate.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Biophysics
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Thomas Schroeder, Nicolaus Kroeger, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Rose-Marie Hamladji, Victoria Potter, Ana Berceanu, Ibrahim Yakoub-Agha, Alessandro Rambaldi, Hakan Ozdogu, Jaime Sanz, Arnon Nagler, Mohamad Mohty
Summary: This study compared two different myeloablative conditioning regimens, FluTBI12 and FB4, before allo-HCT in AML patients. The results showed no significant differences in leukemia-free survival, overall survival, relapse incidence, and non-relapse mortality between the two groups. The incidence of acute and chronic GVHD also showed no statistical differences. In conclusion, FluTBI12 and FB4 are comparable myeloablative regimens for AML patients transplanted in CR1 and CR2.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-Maria Ribera, Renato Bassan, Andrey N. Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foa, Alessandro Rambaldi
Summary: This retrospective study included adult patients with B-cell ALL who were treated with blinatumomab for MRD+ or R/R B-cell ALL. The results showed significant treatment responses and survival benefits in both groups of patients.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Giulia Maggioni, Matteo Bersanelli, Erica Travaglino, Ana Alfonso Pierola, Annika Kasprzak, Arnan Sangerman Montserrat, Elisabetta Sauta, Claudia Sala, Tommaso Matteuzzi, Manja Meggendorfer, Matteo Gnocchi, Lin--Pierre Zhao, Cristina Astrid Tentori, Kathrin Nachtkamp, Daniele Dall'Olio, Ettore Mosca, Marta Ubezio, Alessia Campagna, Antonio Russo, Giulia Rivoli, Massimo Bernardi, Lorenza Borin, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Elena Saba, Saverio D'Amico, Luca Lanino, Benedetta Tinterri, Francesca Re, Marilena Bicchieri, Laura Giordano, Giovanni Angelotti, Pierandrea Morandini, Anne Sophie Kubasch, Francesco Passamonti, Alessandro Rambaldi, Victor Savevski, Armando Santoro, Arjan A. van de Loosdrecht, Alice Brogi, Valeria Santini, Shahram Kordasti, Guillermo Sanz, Francesc Sole, Norbert Gattermann, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Ulrich Germing, Maria Diez--Campelo, Matteo G. Della Porta
Summary: This study aimed to describe sex diversity in myelodysplastic syndromes and incorporate sex information into clinical decision-making. The study found differences between men and women in terms of disease genotype, phenotype, and clinical outcomes. Moreover, new prognostic models that included sex information were developed and performed better than the revised International Prognostic Scoring System.
LANCET HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
Andrea Duminuco, Alessandra Cupri, Rosario Massimino, Salvatore Leotta, Giulio Antonio Milone, Bruno Garibaldi, Giulia Giuffrida, Orazio Garretto, Giuseppe Milone
Summary: A study was conducted to validate the use of portable ultrasound devices in hematopoietic stem cell transplant. The results showed a close correlation and substantial agreement between the conventional and handheld ultrasound devices in measuring various parameters, which can assist in the diagnosis of sinusoidal obstruction syndrome/veno-occlusive disease.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Andrea Duminuco, Salvatore Scarso, Alessandra Cupri, Nunziatina Laura Parrinello, Loredana Villari, Grazia Scuderi, Giuliana Giunta, Salvatore Leotta, Giulio Antonio Milone, Giulia Giuffrida, Giuseppe Alberto Palumbo, Giuseppe Milone
Summary: Ruxolitinib, a JAK1/2 inhibitor, has revolutionized the treatment of myelofibrosis by improving symptoms but also increasing the risk of immunosuppression-related infections. Limited information is available regarding parasitic infections, particularly leishmaniasis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Alessandra Larocca, Lorenzo Cani, Giuseppe Bertuglia, Benedetto Bruno, Sara Bringhen
Summary: While novel therapies have improved outcomes in multiple myeloma (MM), physicians are calling for greater caution when managing this hematologic malignancy in older patients due to their fragility, which increases their vulnerability to toxic events. Additionally, this patient population may be excluded from clinical trials due to comorbidities, whereby available data are not always applicable in real-word clinical practice. This review delves into available frailty assessment tools that can be used to identify patients who are unfit or frail and tailor therapy to achieve better outcomes while minimizing toxicity. Current therapeutic strategies for managing transplant-ineligible patients with newly diagnosed MM and relapsed or refractory MM are also described, with the aim of guiding physicians when selecting treatment options.
Review
Oncology
Federico Lussana, Gianluca Cavallaro, Pantaleo De Simone, Alessandro Rambaldi
Summary: In this review, the impact of novel immune therapies on the treatment of acute lymphoblastic leukemia (ALL) in children and adults was discussed. Results from trials evaluating the incorporation of these new drugs into frontline treatments show promising clinical benefit. Clinical conditions, such as high tumor burden or extra medullary relapse, still have poor clinical outcome despite the promising results. Combination of immunotherapies with chemotherapy in frontline treatment is being evaluated to increase the rate and depth of molecular remission. The use of tyrosine kinase inhibitors and immunotherapy in Ph-positive ALL has shown unprecedented rates of remission and long-term cure. The development of potentially curative treatment modalities for older ALL patients who cannot receive intensive chemotherapy is also highlighted.
Article
Pharmacology & Pharmacy
Chun Liu, Pier Giorgio Cojutti, Maddalena Giannella, Marcello Roberto, Beatrice Casadei, Gianluca Cristiano, Cristina Papayannidis, Nicola Vianelli, Pier Luigi Zinzani, Pierluigi Viale, Francesca Bonifazi, Federico Pea
Summary: CAR T-cell therapy may cause cytokine release syndrome (CRS) and acute kidney injury, potentially affecting the pharmacokinetics of beta-lactam drugs. This study found that the clearance of meropenem and piperacillin did not need to be reduced in CAR T-cell patients experiencing CRS.
Article
Biology
Alberto Magi, Gianluca Mattei, Alessandra Mingrino, Chiara Caprioli, Chiara Ronchini, GianMaria Frige, Roberto Semeraro, Davide Bolognini, Alessandro Rambaldi, Anna Candoni, Emanuela Colombo, Luca Mazzarella, Pier Giuseppe Pelicci
Summary: DNA methylation patterns in sparse CpG regions drive chemoresistance in Acute Myeloid Leukemia patients.
COMMUNICATIONS BIOLOGY
(2023)
Correction
Biology
Alberto Magi, Gianluca Mattei, Alessandra Mingrino, Chiara Caprioli, Chiara Ronchini, Gianmaria Frige, Roberto Semeraro, Davide Bolognini, Alessandro Rambaldi, Anna Candoni, Emanuela Colombo, Luca Mazzarella, Pier Giuseppe Pelicci
COMMUNICATIONS BIOLOGY
(2023)
Article
Transplantation
Michele Malagola, Nicola Polverelli, Massimo Martino, Francesca Patriarca, Benedetto Bruno, Luisa Giaccone, Giovanni Grillo, Stefania Bramanti, Paolo Bernasconi, Marco De Gobbi, Annalisa Natale, Elisabetta Terruzzi, Attilio Olivieri, Patrizia Chiusolo, Angelo Michele Carella, Marco Casini, Enrico Maffini, Chiara Nozzoli, Patrizio Mazza, Simona Bassi, Francesco Onida, Adriana Vacca, Sadia Falcioni, Mario Luppi, Anna Paola Iori, Vincenzo Pavone, Cristina Skert, Paola Carluccio, Carlo Borghero, Anna Proia, Carmine Selleri, Vicky Rubini, Nicoletta Sacchi, Elena Oldani, Francesca Bonifazi, Fabio Ciceri, Domenico Russo
Summary: This study analyzed data from allogeneic stem cell transplants performed in elderly patients with acute myeloid leukemia or myelodysplastic syndrome in Italy between 2006 and 2017. Patients were grouped based on the type of alkylator used in the conditioning regimen. The results showed no significant differences in overall survival, cumulative incidence of relapse, and nonrelapse mortality between the two groups.
TRANSPLANTATION DIRECT
(2023)
Article
Biophysics
Giuseppe Milone, Salvatore Leotta, Giulia Giuffrida, Giulio Antonio Milone, Gabriele Sapuppo, Giuliana Giunta, Benedetta Esposito, Dario Leotta, Sebastiano Fiore, Chiara Pennisi, Linda Longo, Alessandra Cupri
Summary: This study investigated the prognostic value of the dynamic progression of cutaneous to visceral involvement in acute graft-versus-host disease (a-GVHD). The results showed that the dynamic of skin GVHD could be used to classify a-GVHD and guide treatment for skin-only Grade 1 GVHD.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Oncology
Giuseppe Mele, Nicola Di Renzo, Nicola Cascavilla, Angelo Michele Carella, Attilio Guarini, Patrizio Mazza, Lorella Melillo, Vincenzo Pavone, Giuseppe Tarantini, Paola Curci, Anna P. Falcone, Candida Germano, Anna Mele, Francesca Merchionne, Giulia Palazzo, Gaetano Palumbo, Angela Maria Quinto, Giovanni Reddiconto, Bernardo Rossini, Alessandro Spina, Nicola Sgherza, Giorgina Specchia, Pellegrino Musto, Domenico Pastore
LEUKEMIA & LYMPHOMA
(2023)
Letter
Oncology
Alessandra Carobbio, Alessandro Maria Vannucchi, Elisa Rumi, Valerio De Stefano, Alessandro Rambaldi, Giuseppe Carli, Maria Luigia Randi, Heinz Gisslinger, Francesco Passamonti, Juergen Thiele, Naseema Gangat, Ayalew Tefferi, Tiziano Barbui
BLOOD CANCER JOURNAL
(2023)
Article
Medicine, Research & Experimental
Ilaria Laurenzana, Luciana De Luca, Pietro Zoppoli, Giovanni Calice, Alessandro Sgambato, Angelo Michele Carella, Antonella Caivano, Stefania Trino
Summary: The methylation profile of HSPCs following AHSCT was analyzed and found to undergo changes that may be useful in transplant diagnostics. The methylation signature was also found to be related to patient outcome. This study suggests that the methylation profile of HSPCs can provide prognostic information for engraftment success and graft failure prediction in AHSCT.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)